ARTICLE SUMMARY:
After several ultra-challenging years for Integra LifeSciences, Chair and shareholder Stuart Essig is stepping back into the CEO role, with ambitions to accelerate the company’s turnaround. Wall Street remains wary, despite Essig’s previous successes.
Integra LifeSciences Holdings Corp., a fixture in the neurology and wound care subsectors of medtech for decades, in recent years has struggled with compliance issues, supply chain shortages, and voluntary recalls that have shaken its core businesses.
It has undergone three CEO changes in the past five years, most recently in early May, when the company abruptly announced current Chair and former CEO Stuart Essig, PhD, would replace Mojdeh Poul, who had assumed the CEO role in January 2025.
Essig is a familiar name associated with the company—he was CEO during the highly successful years of 1997 to 2011, and chairman thereafter. Under his leadership as CEO, the company grew steadily through a series of new product introductions, small acquisitions, and sales force expansions, all focusing on neurosurgery and tissue reconstruction technologies. But his latest move was a surprise.
